{"id":18803,"date":"2015-05-11T11:43:16","date_gmt":"2015-05-11T09:43:16","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=18803"},"modified":"2015-05-11T11:43:16","modified_gmt":"2015-05-11T09:43:16","slug":"piccole-pharma-in-cima-classifica-2014-aziende-piu-redditizie","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/piccole-pharma-in-cima-classifica-2014-aziende-piu-redditizie\/","title":{"rendered":"Small pharma tops 2014 most profitable companies ranking"},"content":{"rendered":"<p><em>In first place Amag with a profit margin of 109%<\/em><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"https:\/\/www.okta.com\/blog\/wp-content\/uploads\/2013\/05\/imgres.jpeg\" alt=\"\" width=\"158\" height=\"158\" \/>What are the most profitable pharmaceutical companies of 2014? Surprisingly, at the top of the ranking compiled by Motley Fool there are not big names, but small companies. As <strong>Amag Pharmaceuticals<\/strong>, who built her fortune on an anemia drug called Feraheme, which made her number one. Last year, its profit margin stood at 109%.<\/p>\n<p>c<img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/photos.prnewswire.com\/prnvar\/20110822\/SF55808LOGO\" alt=\"\" width=\"175\" height=\"79\" \/>Of course, the result was due to a one-time tax benefit that boosted net income. An unrepeatable feat. There is then <strong>PDL BioPharma<\/strong>: Its 2014 margin was around 66%, says the Motley Fool. It&#039;s not a typical pharmaceutical company, though: most of its revenues come from royalties: for example, 71% of 2014 revenues came from a drug licensed to Roche&#039;s unit, Genentech.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/images.finanzen.net\/mediacenter\/unsortiert\/enanta_pharmaceuticals_by_org_260.jpg\" alt=\"\" width=\"215\" height=\"99\" \/>The third company is the most interesting: it is still small, with just $57.4 million in revenues in the first quarter. But the success of <strong>Enanta Pharmaceuticals<\/strong> depends on a widespread disease \u2013 hepatitis C \u2013 and in particular the royalties on Abbvie&#039;s newly approved drug cocktail Viekira Pak. For example, as much as $50 million came from milestones for the European approval of the treatment. Its 2014 profit margin was 65%.<\/p>\n<p>The only two midsize pharmaceutical companies with attractive margins are Shire and Gilead Sciences. Shire&#039;s margin was 56%, while Gilead stands at 48%.<\/p>\n<p><a href=\"http:\/\/streamer.adnkronos.com\/Salute\/Newsletter\/data\/Pk84e15.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Barbara Di Chiara \u2013 11 May 2015 \u2013 Pharma<em>Kronos<\/em><\/span><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Al primo posto Amag con un margine di profitto del 109% Quali sono le aziende farmaceutiche pi\u00f9 redditizie del 2014? A sorpresa, in cima alla classifica compilata da Motley Fool non ci sono grandi nomi, bens\u00ec piccole societ\u00e0. Come Amag Pharmaceuticals, che ha costruito la sua fortuna su un medicinale contro l&#8217;anemia chiamato Feraheme, grazie &hellip;<\/p>","protected":false},"author":4,"featured_media":18807,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-18803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18803"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18803\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/18807"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}